LONDON (AP) - Europe’s top drug regulator has recommended approval for the first vaccine against meningitis B, made by Novartis AG.
There are five types of bacterial meningitis. While vaccines exist to protect against the other four, none has previously been licensed for type B meningitis. In Europe, type B is the most common, causing several thousand cases every year.
Meningitis mainly affects infants and children. It kills about 8 percent of patients and leaves others with lifelong consequences, like brain damage.
In a statement on Friday, Andrin Oswald of Novartis said he was “proud of the major advance” the company had made in developing its vaccine Bexsero.
Recommendations from the European Medicines Agency are usually adopted by the European Commission. Novartis is also seeking to test the vaccine in the U.S.
By Douglas Holtz-Eakin
The young drop coverage to avoid higher premiums
Independent voices from the TWT Communities
Join the Communities and submit your column in response to one written, or on something totally new and unique. We want to hear from you
Health care reform, organized medicine, physician practice management, and patient care--a real time look at the challenges facing doctors and patients in America today.
Benghazi: The anatomy of a scandal
13 Photos
Vietnam Memorial adds four names
18 Photos
Cinco de Mayo on the Mall
11 Photos
NRA kicks off annual convention
8 Photos
California wildfires wreak havoc
37 Photos
